Group sequential testing for cluster randomized trials with time-to-event endpoint

被引:0
|
作者
Li, Jianghao [1 ]
Jung, Sin-Ho [1 ]
机构
[1] Duke Univ, Dept Biostat & Bioinformat, Sch Med, Durham, NC 27705 USA
关键词
alpha spending function; dependent increment; expected sample size; intracluster correlation coefficient; log-rank test; variable cluster size; MAXIMUM DURATION; LOGRANK TESTS; DESIGN;
D O I
10.1111/biom.13498
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We propose group sequential methods for cluster randomized trials (CRTs) with time-to-event endpoint. The alpha spending function approach is used for sequential data monitoring. The key to this approach is determining the joint distribution of test statistics and the information fraction at the time of interim analysis. We prove that the sequentially computed log-rank statistics in CRTs do not have independent increment property. We also propose an information fraction for group sequential trials with clustered survival data and a corresponding sample size determination approach. Extensive simulation studies are conducted to evaluate the performance of our proposed testing procedure using some existing alpha spending functions in terms of expected sample size and maximal sample size. Real study examples are taken to demonstrate our method.
引用
收藏
页码:1353 / 1364
页数:12
相关论文
共 50 条
  • [31] Estimating the Treatment Effect in a Subgroup Defined by an Early Post-Baseline Biomarker Measurement in Randomized Clinical Trials With Time-To-Event Endpoint
    Bornkamp, Bjoern
    Bermann, Georgina
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (01): : 19 - 28
  • [32] Local Time-to-Event Endpoint Under-Reporting and Variability in Pancreatic Cancer Trials Involving Radiotherapy
    Lin, T. A.
    Mao, S.
    Anker, C.
    Herman, J. M.
    Meyer, J. J.
    Narang, A.
    Hu, C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E316 - E317
  • [33] Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint
    Bruckner, Matthias
    Titman, Andrew
    Jaki, Thomas
    [J]. STATISTICS IN MEDICINE, 2017, 36 (20) : 3137 - 3153
  • [34] Validation of a longitudinally measured surrogate marker for a time-to-event endpoint
    Renard, D
    Geys, H
    Molenberghs, G
    Burzykowski, T
    Buyse, M
    Vangeneugden, T
    [J]. JOURNAL OF APPLIED STATISTICS, 2003, 30 (02) : 235 - 247
  • [35] Bayesian optimal phaseIIclinical trial design with time-to-event endpoint
    Zhou, Heng
    Chen, Cong
    Sun, Linda
    Yuan, Ying
    [J]. PHARMACEUTICAL STATISTICS, 2020, 19 (06) : 776 - 786
  • [36] Sample size calculation for time-to-event data in stepped wedge cluster randomised trials
    Takanashi, Fumihito
    Keding, Ada
    Crouch, Simon
    Kanaan, Mona
    [J]. TRIALS, 2016, 17
  • [37] From Logic-Respecting Efficacy Estimands to Logic-Ensuring Analysis Principle for Time-to-Event Endpoint in Randomized Clinical Trials with Subgroups
    Liu, Yi
    Yang, Miao
    Kil, Siyoen
    Li, Jiang
    Mondal, Shoubhik
    Shentu, Yue
    Tian, Hong
    Wang, Liwei
    Yung, Godwin
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 560 - 573
  • [38] Comparison of Time-to-Event Data for Clinical Trials
    Nadarajah, Saralees
    [J]. MONTE CARLO METHODS AND APPLICATIONS, 2007, 13 (01): : 21 - 35
  • [39] Designing group sequential randomized clinical trials with time to event end points using a R function
    Filleron, Thomas
    Gal, Jocelyn
    Kramar, Andrew
    [J]. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2012, 108 (01) : 113 - 128
  • [40] Guidelines for time-to-event endpoints' definitions in cancer randomized controlled trials (RCTs) for breast cancer - results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Gourgou-Bourgade, S.
    Dabakuyo-Yonli, S.
    Cameron, D.
    Cardoso, F.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S441 - S442